Nicox says China regulator accepts NCX 470 NDA for review
XLV•License fees and royalties
Nicox has received EUR 18 million in license fees from Ocumension; royalties on sales are set at 6%-12%.
China regulator accepts NCX 470 application for review
China’s NMPA accepted for review the New Drug Application for Nicox’s NCX 470 glaucoma treatment, filed by licensee Ocumension Therapeutics.
Regulatory decision typically takes 12-18 months from submission; review follows an August filing.
